Patients must have unresectable or metastatic, histologically confirmed low or intermediate grade (Klimstra Criteria) pancreatic neuroendocrine tumor (PNET) with radiological evidence of disease progression since last treatment
Fungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 month
Radiological progression (confirmed at least 4 weeks after the initial scan showing PD); or
Patients with fungal pneumonia with radiological progression after receipt of amphotericin formulation or mold-active azoles for greater than 1 month will not be eligible for this protocol
Patient must have progressed on their most recent line of therapy. Progression must have been demonstrated by radiological or clinical assessment.
Radiological or objective evidence of recurrence or progression on or after the last systemic therapy prior to enrollment
Documented radiological evidence for disease progression (measurable or nonmeasurable) =< 12 months prior to enrollment
Radiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI, e.g., gefitinib or erlotinib. In addition, other lines of therapy may have been given. All patients must have documented radiological progression on the last treatment administered, prior to enrolling in the study.
Diagnosis of radiological progression while on or after first platinum-based systemic therapy
Has radiological documentation of disease progression while receiving continuous treatment with erlotinib, gefitinib, or afatinib.
Fungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 month
Patients must have radiological evidence of disease progression following the most recent treatment
Surgical or radiological treatment of lesions contraindicated
Inability to undergo contrast radiological assessments
Failure of at least one line of systemic anti-cancer therapy for advanced NSCLC defined as either of the following: \r\na) Radiological documentation of disease progression (or failure to achieve a response) or \r\nb) Discontinuation due to toxicity
The patient must have documented disease limited to the peritoneal surface, amenable to complete cytoreduction indicated by:\r\n* Disease confined to the peritoneal surfaces\r\n* No parenchymal liver metastases\r\n* No evidence of clinical, biochemical or radiological biliary obstruction\r\n* Small volume of disease in the gastro-hepatic ligament defined by a < 5 cm mass in the epigastric region on cross-sectional imaging\r\n* No clinical or radiological evidence of hematogenous or distant nodal metastasis
Patients with clinical or radiological evidence of bone (>= 3 sites, or predominantly lytic if < 3) or other extranodal metastasis
Patients with fungal infection and radiological progression after receipt of amphotericin B or active triazole for greater than 1 month
No clinical or radiological evidence of metastatic disease or local progression
Patients must have documented radiological disease progression either during or after the first-line therapy.
Radiological documentation of disease progression:
No evidence of metastatic disease by clinical and radiological staging
For the purpose of obtaining a RECIST v1.1 baseline scan, participants must have a\n             radiological evaluation conducted no more than 28 days prior to beginning study\n             therapy (PLD).  NOTE: For participants with a history of CNS metastasis, baseline\n             radiological imaging must include an evaluation of the head.
Radiological evidence of metastatic disease
Patients with fungal pneumonia with radiological progression after receipt of amphotericin formulation or mold-active azoles for greater than 1 month will not be eligible for this protocol (either regimen A or B)
Radiological evidence of CNS metastases
Fungal infections with radiological progression after receipt of amphotericin product or active triazole for > 1 month
Definitive clinical or radiological evidence of metastatic disease
Fungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 month
Radiological stage T1-T2 N0 Mx/M0 disease.
Radiological evidence of multifocal disease, tumors extending into or crossing the corpus callosum or leptomeningeal disease.
Radiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI. Additional other lines of therapy may have been given. All patients must have documented radiological progression on the last treatment administered prior to enrolling in the study.
Documented radiological disease progression during the most recent treatment regimen for metastatic disease
Radiological documentation of disease progression following 1st line EGFR TKI Treatment without any further treatment
Evidence of at least one measurable lesion as detected by radiological or photographic methods
Radiological evidence for progressive disease (measurable or non-measurable) within 12 months prior to registration; patients who have received anti-tumor therapy during the past 12 months (including octreotide analogs) must have had radiological documentation of progression of disease while on or after receiving therapy
Radiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI e.g. gefitinib or erlotinib (with the exception of 1st line expansion cohort). In addition other lines of therapy may have been given. All patients must have documented radiological progression on the last treatment administered prior to enrolling in the study.
Evidence of at least one measurable lesion as detected by radiological or photographic methods
Objective evidence of disease progression (clinical or radiological) during or after at least 1 (V600 Wildtype) or at least 2 (V600 mutation positive) prior treatment regimens
Patients with clinical, radiological/laboratory, or pathological evidence of distant metastatic disease
Fungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 month
Radiological suspicion of pseudoprogression or radionecrosis
Patients with fungal pneumonia with radiological progression after receipt of amphotericin formulation or mold-active azoles for greater than 1 month
Clinical or radiological evidence of metastatic disease
Has radiological documentation of disease progression while receiving continuous treatment with erlotinib, gefitinib, afatinib, or osimertinib
